Danielle-Roberts(updated) - Headshot

Danielle Roberts,

MS, MMSc, PA-C

Danielle Roberts,

MS, MMSc, PA-C

Associate Chief of Education, Winship Cancer Institute of Emory University

Danielle-Roberts(updated) - Headshot

Danielle Roberts,

MS, MMSc, PA-C

Associate Chief of Education, Winship Cancer Institute of Emory University

Danielle Roberts serves as the director for the APP Fellowship Program. She graduated from Emory University’s Physician Assistant Program in 2007. Upon graduation, Danielle worked in community oncology before joining the Winship Cancer Institute in 2011.  She has enjoyed working in many oncologic specialties including community oncology, survivorship, GVHD, and in her current position in malignant hematology. Danielle currently serves as the Associate Chief of Education for the Winship Cancer Institute and is Society Leader and adjunct faculty for the Emory University Physician Assistant Program.  She recently graduated from the WHEA Teaching Fellowship and was honored with the 2022 Physician Assistant of the Year by the Emory Physician Assistant program.

Provided by an unrestricted grant from

Danielle-Roberts - Headshot

Danielle's Shared Resources

Dexamethasone Dose Reductions in NDMM: No Impact on Survival Outcomes

Dexamethasone is a key component of induction therapy for newly diagnosed multiple myeloma (NDMM), but its use is often associated with toxicities such as hyperglycemia and insomnia....
CURATED BY:
Danielle Roberts,
MS, MMSc, PA-C

Challenges and Hope in Treating RRMM: Insights from the LocoMMotion Study

Researchers from the LocoMMotion study examined real-world clinical practice treatments for patients with relapsed/refractory multiple myeloma (RRMM) exposed to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies....
CURATED BY:
Danielle Roberts,
MS, MMSc, PA-C

Multiple Myeloma Advances Call for Standardized IgG-RT to Tackle Immune Challenges

Recent advancements in multiple myeloma (MM) therapies have extended survival but introduced immunosuppressive challenges, including hypogammaglobulinemia, which increases infection risk. T-cell engaging therapies have improved outcomes for heavily pretreated patients,...
CURATED BY:
Danielle Roberts,
MS, MMSc, PA-C

Provided by an unrestricted grant from

Share